To encourage drug companies to seek approval for over-the-counter versions of naloxone, an emergency treatment for opioid overdose, the Food and Drug Administration today released model consumer-friendly labels for prospective OTC versions of the drug. FDA-approved versions of naloxone currently require a prescription, which “may be a barrier for people who aren’t under the care of a physician or may be ashamed or even fearful of admitting to issues with substance abuse,” said FDA Commissioner Scott Gottlieb, M.D. Before submitting a new drug application or supplement for an OTC drug product, companies must develop a Drug Facts Label and conduct studies to show that consumers can understand how to use the product without the supervision of a health care professional. “Some stakeholders have identified the requirement to perform these studies as a barrier to development of OTC naloxone products,” Gottlieb said. “To encourage drug companies to enter the OTC market and increase access to naloxone, the FDA took an unprecedented step: we developed a model DFL with easy-to-understand pictograms on how to use the drug. We also conducted label comprehension testing to ensure the instructions were simple to follow.”

Related News Articles

Headline
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the…
Headline
April 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
Critical Access Hospitals, certain clinics, and other eligible outpatient facilities that provide primary care or substance use disorder treatment to high-need…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.